“Neovacs’ unique approach allows us to produce innovative treatments intended to be curative and accessible to all patients suffering from autoimmune diseases. Beyond product development, in order to ensure the production of its technology, Neovacs also operates Neostell, a production site for all of the company’ Kinoids®. To support our research work, we have assembled a team of leading international specialists. Our hope is that these investments will produce the emergence of treatments that will make a substantial difference in healthcare.”
Miguel Sieler brings over 32 years experience in the pharmaceutical and chemical industry.
Miguel Sieler joined Bayer AG, Leverkusen, (Germany) in 1975 for an international career which started at the group headquarters in Germany. He further served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea, followed by 4 years as C.E.O of Bayer Pharma France. In 1998, Miguel Sieler became Chairman and C.E.O of the Bayer Group in France. Miguel Sieler holds a Master of Law from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.
He joined Neovacs in 2005, he was previously Senior –VP- PD, of Flamel Technologies and previously Corporate VP, Global Industrialization, at Sanofi Pasteur.
Degree in biological chemistry from the University of Lyon, France
She joined Neovacs in 2015. Formerly, CMO at Cytheris for over 6 years, a French biotech company acting in active immunotherapy, before as Director of BU Lauriad & NCE at Onxeo following several years at Novo Nordisk as EU Medical Adviser for NovoSeven®She worked for 10 years at Bayer, as International Project Leader for Kogenate®
Medical degree from the Catholic University of Louvain, Brussels, Belgium.
He joined Neovacs in 2005.
Previously Head of CMC at Anosys and research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute. Degree in Pharmacy (Paris XI University, France) and a PhD in Virology (Pierre et Marie Curie University, France).
She joined Neovacs in 2018.
WHY SHOULD YOU INVEST IN NEOVACS ?GO TO THE INVESTORS SECTION